Blood Pharming
Abstract
(U)The overall Blood Pharming program objective is to develop an automated culture and packaging system that yields transfusable levels of universal donor red blood cells (RBCs) from progenitor cell sources. The goal of the Phase II effort is to produce 100 units of universal donor (Type O negative) RBCs per week for eight weeks in an automated closed culture system using a renewing progenitor population. Central to Phase II work will be the demonstration of a two hundred million-fold expansion of progenitor cell populations to mature RBCs. To realize these goals, Phase II will capitalize advances in cell differentiation, expansion, and bioreactor technology developed in Phase I of the program. Successful completion of the Blood Pharming effort will provide a safe donorless blood supply that is the functional equivalent of fresh donor cells, satisfying a large battlefield demand and reducing the logistical burden of donated blood in theater. Phase I was completed in PE 0601101E, Project BLS-01, Biological Adaptation, Assembly and Manufacturing Program.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2011
- Source ID
- 3c37c68f3f0302e5b3202e7ed7a5e12e